Merck & Co., Inc. (NYSE:MRK) Shares Acquired by HBW Advisory Services LLC

HBW Advisory Services LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,281 shares of the company’s stock after purchasing an additional 11,339 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.1% of HBW Advisory Services LLC’s investment portfolio, making the stock its 27th largest holding. HBW Advisory Services LLC’s holdings in Merck & Co., Inc. were worth $4,107,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Norway Savings Bank lifted its stake in Merck & Co., Inc. by 30.4% during the 1st quarter. Norway Savings Bank now owns 6,199 shares of the company’s stock valued at $478,000 after acquiring an additional 1,445 shares during the period. Arvest Bank Trust Division raised its position in Merck & Co., Inc. by 46.4% during the first quarter. Arvest Bank Trust Division now owns 10,807 shares of the company’s stock worth $833,000 after acquiring an additional 3,424 shares during the period. Royal London Asset Management Ltd. raised its holdings in shares of Merck & Co., Inc. by 0.9% during the first quarter. Royal London Asset Management Ltd. now owns 930,444 shares of the company’s stock valued at $71,728,000 after acquiring an additional 7,865 shares during the last quarter. Chicago Capital LLC boosted its position in Merck & Co., Inc. by 4.5% during the first quarter. Chicago Capital LLC now owns 18,856 shares of the company’s stock worth $1,454,000 after acquiring an additional 811 shares during the last quarter. Finally, Gofen & Glossberg LLC IL raised its holdings in shares of Merck & Co., Inc. by 1.1% during the 1st quarter. Gofen & Glossberg LLC IL now owns 419,642 shares of the company’s stock worth $32,350,000 after acquiring an additional 4,623 shares during the period. Hedge funds and other institutional investors own 72.86% of the company’s stock.

Shares of NYSE:MRK traded down $0.11 on Wednesday, hitting $76.32. The company had a trading volume of 232,518 shares, compared to its average volume of 11,827,972. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90. The company has a market cap of $193.12 billion, a PE ratio of 16.91, a PEG ratio of 1.89 and a beta of 0.43. Merck & Co., Inc. has a 52-week low of $71.71 and a 52-week high of $87.80. The business has a 50 day moving average of $75.54 and a 200 day moving average of $78.82.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.06). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The firm had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.65 billion. During the same period in the previous year, the firm posted $1.16 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities analysts predict that Merck & Co., Inc. will post 5.9 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 7th. Investors of record on Monday, March 15th were given a dividend of $0.65 per share. The ex-dividend date of this dividend was Friday, March 12th. This represents a $2.60 dividend on an annualized basis and a yield of 3.41%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 50.10%.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $96.27.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.

Recommended Story: What is net income?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.